



HAL
open science

Capsular Polysaccharide Cross-Regulation Modulates *Bacteroides thetaiotaomicron* Biofilm Formation

Nathalie Béchon, Jovana Mihajlovic, Sol Vendrell-Fernández, Florian Chain,
Philippe Langella, Christophe Beloin, Jean-Marc Ghigo

► **To cite this version:**

Nathalie Béchon, Jovana Mihajlovic, Sol Vendrell-Fernández, Florian Chain, Philippe Langella, et al..
Capsular Polysaccharide Cross-Regulation Modulates *Bacteroides thetaiotaomicron* Biofilm Formation. *mBio*, 2020, 11 (3), 10.1128/mBio.00729-20 . pasteur-03209304

HAL Id: pasteur-03209304

<https://pasteur.hal.science/pasteur-03209304>

Submitted on 27 Apr 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.


L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



Capsular Polysaccharide Cross-Regulation Modulates *Bacteroides thetaiotaomicron* Biofilm Formation

Nathalie Béchon,^{a,b} Jovana Mihajlovic,^{a,b*} Sol Vendrell-Fernández,^a Florian Chain,^c Philippe Langella,^c  Christophe Beloin,^a Jean-Marc Ghigo^a

^aInstitut Pasteur, Genetics of Biofilms Laboratory, Paris, France

^bUniversité de Paris, Ecole Doctorale Bio Sorbonne Paris Cité (BioSPC), Cellule Pasteur, Paris, France

^cCommensals and Probiotics-Host Interactions Laboratory, Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas, France

Nathalie Béchon and Jovana Mihajlovic contributed equally this work. Author order was determined alphabetically.

ABSTRACT *Bacteroides thetaiotaomicron* is one of the most abundant gut symbiont species, whose contribution to host health through its ability to degrade dietary polysaccharides and mature the immune system is under intense scrutiny. In contrast, adhesion and biofilm formation, which are potentially involved in gut colonization and microbiota structure and stability, have hardly been investigated in this intestinal bacterium. To uncover *B. thetaiotaomicron* biofilm-related functions, we performed a transposon mutagenesis in the poorly biofilm-forming reference strain VPI-5482 and showed that capsule 4, one of the eight *B. thetaiotaomicron* capsules, hinders biofilm formation. We then showed that the production of capsules 1, 2, 3, 5, and 6 also inhibits biofilm formation and that decreased capsulation of the population correlated with increased biofilm formation, suggesting that capsules could be masking adhesive surface structures. In contrast, we showed that capsule 8 displayed intrinsic adhesive properties. Finally, we demonstrated that *BT2934*, the *wzx* homolog of the *B. thetaiotaomicron* glycosylation locus, competes with capsule production and impacts its adhesion capacity. This study therefore establishes *B. thetaiotaomicron* capsule regulation as a major determinant of *B. thetaiotaomicron* biofilm formation, providing new insights into how modulation of different *B. thetaiotaomicron* surface structures affects *in vitro* biofilm formation.

IMPORTANCE The human gut harbors a complex bacterial community that plays important roles in host health and disease, including nutrient acquisition, maturation of the immune system, and resistance to infections. The capacity to adhere to surfaces and form communities called biofilms is believed to be important for niche colonization and maintenance of gut bacteria. However, little is known about the adhesion capacity of most gut bacteria. In this study, we investigated biofilm formation in *Bacteroides thetaiotaomicron*, one of the most abundant bacteria of the normal mammalian intestine. We identified that *B. thetaiotaomicron* capsules, a group of eight surface-exposed polysaccharidic layers mediating important interactions with the gut environment, are also major determinants of biofilm formation that mask or unmask adhesion factors. Studying how *B. thetaiotaomicron* regulates its adhesion properties will allow us to better understand the physiology and specific properties of this important gut symbiont within anaerobic biofilms.

KEYWORDS capsule, *Bacteroides thetaiotaomicron*, biofilm

B*acteroides thetaiotaomicron* is an abundant bacterial symbiont of the normal mammalian intestine that contributes to shaping the nutrient environment of the gut microbiome through degradation of complex polysaccharides and production of short-

Citation Béchon N, Mihajlovic J, Vendrell-Fernández S, Chain F, Langella P, Beloin C, Ghigo J-M. 2020. Capsular polysaccharide cross-regulation modulates *Bacteroides thetaiotaomicron* biofilm formation. *mBio* 11:e00729-20. <https://doi.org/10.1128/mBio.00729-20>.

Editor Gary M. Dunny, University of Minnesota Medical School

Copyright © 2020 Béchon et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Jean-Marc Ghigo, jmghigo@pasteur.fr.

* Present address: Jovana Mihajlovic, Center for Microbiology and Environmental Systems Science, Department of Microbiology and Ecosystem Science, Division of Microbial Ecology, University of Vienna, Vienna, Austria.

Received 25 March 2020

Accepted 22 May 2020

Published 23 June 2020

chain fatty acids (1–5). *B. thetaiotaomicron* was also shown to stimulate the development of gut immunity (6), attenuate intestinal inflammation (7), and strengthen the intestinal protective barrier (8, 9). Consistently, a decrease in the abundance of *B. thetaiotaomicron* and other *Bacteroides* species has been correlated with gut inflammation and disease emergence, underlining the importance of the gut microbiota for host intestinal physiology and health (10). In contrast, microbial functions involved in the establishment and maintenance of a healthy gut microbiota are still not well understood. It is speculated that the ability of symbiont bacteria to form biofilms could contribute to microbiota stability (11, 12). However, although bacterial biofilm formation has been studied in various facultative symbiotic and pathogenic anaerobes, information on this widespread lifestyle is still scarce in *B. thetaiotaomicron* (13–15). Whereas comparative gene expression profiling between biofilm and planktonically grown *B. thetaiotaomicron* showed biofilm-associated upregulation of polysaccharide utilization systems and capsule 8, one of the eight *B. thetaiotaomicron* capsule synthesis loci (15, 16), there is still no direct proof of the contribution of these surface structures to adhesion and biofilm formation. We recently showed that although biofilm capacity is widespread among *B. thetaiotaomicron* isolates, the widely used reference strain VPI-5482 is a poor biofilm former. Nevertheless, use of transposon mutagenesis followed by a positive selection procedure revealed mutants with significantly improved biofilm capacity due to alteration of the structure of a putative type V pilus (13). Here, we identified two mechanisms of capsule regulation in *B. thetaiotaomicron*, involving UpxZ-mediated capsule transcription inhibition and competition between protein glycosylation and capsule production. We showed that capsule masking or unmasking of adhesive structures is a major determinant of *B. thetaiotaomicron* biofilm formation. This study therefore provides new insights into the roles of capsular polysaccharides in *B. thetaiotaomicron* and their impact on the physiology and biofilm formation of a prominent gut symbiont.

RESULTS

Transposon insertion in the capsule 4 biosynthesis operon promotes *B. thetaiotaomicron* biofilm formation. Among the previously identified transposon mutants displaying increased *in vitro* biofilm formation capacity compared to the wild-type *B. thetaiotaomicron* VPI-5482 (WT) (13), five of them corresponded to insertions within capsule 4 (*CPS4*) synthesis operon *BT1358-1338*, encoding one of the eight capsular polysaccharides of *B. thetaiotaomicron* (Fig. 1A and B; see Table S1 in the supplemental material) (16, 17). To confirm the increased biofilm phenotype of the transposon mutants, we deleted all 19 *CPS4* structural genes located downstream of the regulators *BT1358-1357*. Crystal violet staining of *in vitro* biofilm formed in 96-well microtiter plates showed that the resulting $\Delta BT1356-1338$ mutant (here named $\Delta CPS4$) displayed a significant increase in biofilm formation compared to the wild-type *B. thetaiotaomicron* VPI-5482 (Fig. 1C).

***B. thetaiotaomicron* biofilm formation is modulated by capsule cross-regulation.** To uncover the mechanism of increased biofilm formation in a $\Delta CPS4$ strain, we performed a random transposon mutagenesis in $\Delta CPS4$ and identified 6 mutants out of 4,650 with reduced biofilm formation capacity compared to the parental $\Delta CPS4$ (Fig. 2A). Five of these mutants corresponded to transposons inserted in the *BT1358-1357* region just upstream of the *CPS4* operon (Fig. 1A and Fig. 2B; Table S1). *BT1358* codes for an UpxY-like homolog and *BT1357* codes for a UpxZ-like homolog, two regulatory genes located at the beginning of most capsule synthesis operons in *B. thetaiotaomicron* and *Bacteroides fragilis* (18, 19). UpxY-like proteins positively regulate their cognate capsular operon by preventing premature transcription termination in the untranslated region, thus facilitating the otherwise abortive transcription of the downstream capsular genes (18). In contrast, UpxZ-like proteins are repressors of transcription of nonadjacent capsular systems (19). We first showed that deletion of *upxY^{BT1358}* in *B. thetaiotaomicron* $\Delta CPS4$ did not impact biofilm formation, which is consistent with its role as a positive regulator of the expression of capsule 4 genes, all




FIG 1 Capsule 4 inhibits biofilm formation in *B. thetaiotaomicron* VPI-5482. (A) Organization of *B. thetaiotaomicron* capsular operon 4 (*CPS4*). The first two genes (*BT1358* and *BT1357*) code regulators of capsular biosynthesis. *BT1356-1338* code the enzymes involved in *Cps4* capsular polysaccharide biosynthesis. The arrows indicate 5 individual transposon insertions within the *CPS4* operon. (B) The 96-well plate biofilm assay after 48 h of growth in BHIS. The Mean of the WT is adjusted to 100%. In the min-max boxplot of 6 biological replicates for each strain, each replicate is the mean of two technical replicates. ***, $P < 0.0005$; Mann-Whitney test, comparing the indicated mutant to the WT. (C) The 96-well plate biofilm assay after 48 h of growth in BHIS. The mean of the WT is adjusted to 100%. In the min-max boxplot of 6 to 9 biological replicates for each strain, each replicate is the mean of two technical replicates. ***, $P < 0.0005$; Mann-Whitney test, comparing the indicated mutant to the WT. The images shown under each boxplot correspond to representative CV-stained microtiter wells after resuspension of the biofilm.

missing in the $\Delta CPS4$ mutant (Fig. 2B and C). We then hypothesized that transposon insertion in $upxY^{BT1358}$ (located upstream of $upxZ^{BT1357}$) could have a polar effect on the expression of the repressor $upxZ^{BT1357}$, leading to the derepression of one or more of the 7 other *B. thetaiotaomicron* capsular polysaccharides. Indeed, in-frame deletion of $upxZ^{BT1357}$ or $upxY^{BT1358}$ - $upxZ^{BT1357}$ in a $\Delta CPS4$ background did not affect growth but led to loss of biofilm capacity (Fig. 2C and Fig. S1A). This phenotype could be




FIG 2 Capsule cross-regulation modulates biofilm formation in *B. thetaiotaomicron*. (A) The 96-well plate crystal violet biofilm assay after 48 h of growth in BHIS. (B) Organization of *B. thetaiotaomicron* capsular operon 4 (*CPS4*) with identified transposon insertion points in the first two genes of the operon (*BT1358* and *BT1357*), coding regulators of capsular biosynthesis. (C) The 96-well plate crystal violet biofilm assay after 48 h of growth in BHIS. The Mean of the WT is adjusted to 100%. (D) The 96-well plate crystal violet biofilm assay after 48 h of growth in BHIS. In panels A, C, and D, the mean of the WT is adjusted to 100%. In the min-max boxplot of 6 to 9 biological replicates for each strain, each replicate is the mean of two technical replicates. **, $P < 0.005$; Mann-Whitney test. *upxY*, $upxY^{BT1358}$; *upxZ*, $upxZ^{BT1357}$.




FIG 3 Capsule expression in *B. thetaioaomicron* is heterogenous and has consequences for biofilm formation. (A and D) The 96-well plate biofilm assay after 48 h of growth in BHIS. The mean of the WT is adjusted to 100%. In the min-max boxplot of 6 biological replicates for each strain, each replicate is the mean of two technical replicates. **, $P < 0.005$; Mann-Whitney test, comparing the indicated mutant to the WT. The pictures shown under the boxplot in panel A correspond to representative CV-stained microtiter wells after resuspension of the biofilm. (B) Transmission electron microscopy (TEM) images of overnight cultures fixed with ferritin. Arrows indicate some examples of acapsulated cells. (C) Percentage of acapsulated cells of indicated strains counted on TEM pictures. For each strain, at least 100 cells were counted. ***, $P < 0.0005$; prop.test (R). *upxY*, *upxY^{BT1358}*; *upxZ*, *upxZ^{BT1357}*.

complemented in *trans* by introducing *upxZ^{BT1357}* expressed from a constitutive promoter in the 5' untranslated region of the tRNA-Ser chromosomal locus, in either a $\Delta upxZ^{BT1357} \Delta CPS4$ or $\Delta upxY^{BT1358}-upxZ^{BT1357} \Delta CPS4$ *B. thetaioaomicron* background (Fig. 2C). To identify which capsules were repressed by *upxZ^{BT1357}*, we used reverse transcription-quantitative PCR (qRT-PCR) to monitor the expression of each capsular operon, and we observed an increased transcription of capsule 2 (CPS2) in *B. thetaioaomicron* $\Delta upxZ^{BT1357} \Delta CPS4$ compared to the *B. thetaioaomicron* $\Delta CPS4$ single mutant (Fig. S2). Consistently, deletion of the CPS2 operon in the *B. thetaioaomicron* $\Delta upxZ^{BT1357} \Delta CPS4$ background restored biofilm formation capacity (Fig. 2D) Thus, expression of either CPS4, or CPS2 in the absence of CPS4, hinders biofilm formation.

Expression of capsule 8 and lack of any capsules both induce biofilm formation. To assess the contribution of all capsules, besides inhibition by CPS4 or CPS2, to *B. thetaioaomicron* biofilm formation, we used a recently described set of strains expressing only one of the eight *B. thetaioaomicron* capsular types (20). We observed that derivative strains expressing only capsule 1, 2, 3, 4, 5, or 6 formed as little biofilm as wild-type (WT) *B. thetaioaomicron* VPI-5482. Interestingly, strains only expressing CPS7 or CPS8 formed over 35 times more biofilm than the WT strain (Fig. 3A). However, all CPS7-only bacteria seemed to be acapsulated, which is consistent with previous observations suggesting that capsule 7 may not be expressed in tested laboratory conditions (Fig. S3A and B) (20). Indeed, similar to a CPS7-only strain, a strain deleted

for all 8 capsule operons ($\Delta CPS1-8$) formed 40 times more biofilm than the WT (Fig. 3A) and showed a strong aggregation phenotype in overnight cultures (Fig. S3B). In contrast, India ink staining confirmed the presence of a capsule in biofilm-forming (but not aggregating) CPS8-only bacteria, suggesting that capsule 8 could have intrinsic adhesive properties (Fig. S3A and B). These results showed that, except for CPS8 and potentially CPS7, the expression of all capsules hinders *B. thetaiotaomicron* biofilm formation and that acapsulated cells display cell-to-cell aggregation capacity likely driving the observed increased biofilm phenotype.

Deletion of capsule 4 leads to a heterogeneously capsulated bacterial population. To determine whether lack of capsule or expression of the biofilm-promoting capsule 8 was responsible for the observed increased biofilm formation in the $\Delta CPS4$ strain, we used transmission electron microscopy (TEM) and showed that whereas WT *B. thetaiotaomicron* bacteria were almost all capsulated (>98%), ca. 30% of $\Delta CPS4$ cells lacked a visible capsule (Fig. 3B and C). Considering that $\Delta CPS1-8$ formed 4 times more biofilm than $\Delta CPS4$, this suggested a correlation between the increased frequency of noncapsulated cells in the population and the increased ability to form biofilms (Fig. 3A and C). To determine whether capsulated cells in the $\Delta CPS4$ population contributed to adhesion, we deleted, in the $\Delta CPS4$ background, either *CPS8*, the only biofilm-promoting capsule of *B. thetaiotaomicron*, or *CPS7*, for which we could not ascertain the biofilm formation potential using a single CPS-expressing strain. Both the $\Delta CPS4 \Delta CPS7$ and $\Delta CPS4 \Delta CPS8$ mutants had similar biofilm capacity compared to a $\Delta CPS4$ mutant, showing that neither capsule 7 nor 8 contribute to biofilm formation in the absence of capsule 4 (Fig. 3D). Moreover, TEM imaging showed that the non-biofilm-forming $\Delta upxZ^{BT1357} \Delta CPS4$ double mutant was entirely capsulated (due to induction of *CPS2*; Fig. S2), supporting a correlation between increased biofilm formation (Fig. 3A) and the presence of a subpopulation of acapsulated cells in the $\Delta CPS4$ strain (Fig. 3B and C). Consistently, deletion of *CPS2* in the $\Delta upxZ^{BT1357} \Delta CPS4$ background led to the emergence of 37% of acapsulated bacteria in a $\Delta upxZ^{BT1357} \Delta CPS4 \Delta CPS2$ population (Fig. 3B and C) and restored biofilm formation (Fig. 2D).

Identification of BT2934 as a new *B. thetaiotaomicron* inhibitor of capsule expression. In addition to mutation in $\Delta upxZ^{BT1357}$ capsule repressor, we also identified a biofilm-deficient $\Delta CPS4$ transposon mutant (34H5) with an insertion in *BT2934* (Fig. 3A and 4A). The *BT2934-2947* region corresponds to a *B. thetaiotaomicron* protein glycosylation locus (21, 22), in which *BT2934* encodes a homolog of the transmembrane oligosaccharide flippase Wzx (Fig. 4A). We deleted *BT2934* and the 4 putative glycosyl transferase genes, *BT2935-2938*, located in the same operon and confirmed the role of *BT2934-2938* in protein glycosylation, as several bands disappeared from a protein glycosylation profile in the $\Delta CPS4 \Delta BT2934-2938$ and 34H5 mutants compared to $\Delta CPS4$ (Fig. S4). The double mutant $\Delta CPS4 \Delta BT2934-2938$ had no growth defect and displayed a 2-fold decrease in biofilm formation compared to $\Delta CPS4$ (Fig. 4B; Fig. S1B). However, it still formed more biofilm than the original 34H5 transposon mutant in *BT2934*. To determine the origin of this discrepancy, we only deleted *BT2935-2938* glycosyl transferases genes and did not observe reduced biofilm capacity compared to the $\Delta CPS4$ strain. Although we did not succeed in deleting *BT2934* alone, introduction of *pBT2934*, constitutively expressing *BT2934*, in the 34H5 transposon mutant and $\Delta CPS4 \Delta BT2934-38$ mutant restored biofilm formation but still showed an altered protein glycosylation profile (Fig. 4C; Fig. S4). These results suggested that the impact of *BT2934* on biofilm formation did not involve *BT2935-2938* and might not directly involve protein glycosylation. Finally, we showed that while $\Delta CPS4$ and $\Delta CPS4 \Delta BT2935-2938$ bacteria displayed similar level of acapsulated cells (30% and 28%, respectively), $\Delta CPS4 \Delta BT2934-2938$ cells showed full, wild-type levels of capsulation (Fig. 4D and E), reduced back down to over 50% of capsulated cells upon complementation by *pBT2934* (Fig. 4D and E). To identify whether *BT2934* directly inhibited capsule production, we overexpressed *BT2934* in each strain only expressing a single CPS type. We hypothesized that overexpression of *BT2934* in each of these strains could inhibit capsule expression and lead to acapsulation of the whole population, thus leading to aggregation in overnight cultures.




FIG 4 *BT2934* is a novel capsule inhibitor. (A) Organization of the *B. thetaiotaomicron* protein glycosylation *BT2934* locus with identified transposon insertion point. (B and C) The 96-well plate crystal violet biofilm assay after 48 h of growth in BHIS. The mean of the WT is adjusted to 100%. In the min-max boxplot of 6 to 12 biological replicates for each strain, each replicate is the mean of two technical replicates. *, $P < 0.05$; **, $P < 0.005$; ***, $P < 0.0005$; Mann-Whitney test. (D) TEM images of Δ CPS4 Δ BT2934-2938, Δ CPS4 Δ BT2935-2938, and Δ CPS4 Δ BT2934-2938 + pBT2934 overnight cultures fixed with ferritin. The arrows indicate some acapsulated cells as examples. (E) Percentage of acapsulated cells in overnight cultures counted on TEM pictures. For each strain, at least 100 cells were counted. ***, $P < 0.0005$; prop.test (R). (F) Overnight cultures of indicated strains in BHIS. Only Δ CPS1-8 showed aggregation.




FIG 5 *BT2934* and *CPS4* contribute to *in vivo* colonization in axenic mice. Min-max boxplot of CFU/ml/dry weight of feces, numbered from feces from 5 to 10 axenic mice after cocolonization with indicated strains. *, $P < 0.05$; **, $P < 0.005$; ***, $P < 0.0005$; Mann-Whitney test. (A) WT (ermR) versus WT (tetR). (B) WT (ermR) versus $\Delta CPS4$ (tetR). (C) (ermR) versus $\Delta BT2934-2938$ (tetR). (D) $\Delta CPS4$ (ermR) versus $\Delta CPS4\Delta BT2934-2938$ (tetR).

However, none of the resulting strains aggregated, suggesting that no capsules were directly inhibited by an overexpression of *BT2934*. Taken together, these results suggest that *BT2934* indirectly impacts capsule production in *B. thetaiotaomicron*, with consequences affecting its ability to form biofilm.

Biofilm-forming *CPS4* and *BT2934* mutants are outcompeted by the wild-type strain *in vivo*. *CPS4* and *BT2934* have previously been shown to be important for *in vivo* colonization in the presence of a complex mix of *B. thetaiotaomicron* transposon mutants (23). To test whether unmasking *B. thetaiotaomicron* biofilm formation capacity could contribute to *in vivo* colonization, we used intragastric gavage to inoculate axenic mice with erythromycin-resistant WT-*erm*- and tetracycline-resistant $\Delta CPS4$ -*tet* or $\Delta BT2934-38$ -*tet* in a 1:1 mix ratio and measured the abundance of each strain in feces for 8 days using erythromycin and tetracycline resistance to discriminate between the strains. We first verified that the *erm* and *tet* resistance markers did not impact *in vivo* colonization of erythromycin-resistant WT (WT-*erm*) and tetracycline-resistant WT (WT-*tet*) (Fig. 5A). We then showed that both the $\Delta CPS4$ and $\Delta BT2934-38$ mutants were outcompeted by the WT strain in two-strain cocolonization experiments (Fig. 5B and C), even though both $\Delta CPS4$ and $\Delta BT2934-38$ formed more biofilm than the WT (Fig. 1C; see also Fig. S5 in the supplemental material). When we tested colonization of the double mutant $\Delta CPS4 \Delta BT2934-2938$ against the $\Delta CPS4$ mutant, we found that they colonized mice similarly (Fig. 5D), indicating that *BT2934* is necessary for colonization only in the WT but not in the $\Delta CPS4$ background. Taken together, these results showed that increased *in vitro* biofilm formation capacity is not predictive of *in vivo* colonization capacity.

DISCUSSION

In contrast to oral *Bacteroidales*, intestinal *Bacteroidales* species possess numerous capsular polysaccharide loci that play important beneficial roles during gut colonization, ranging from protecting bacteria from stresses to mediating interactions with the host immune system (17, 20, 24–26). In this study, we showed that deletion of one of *B. thetaiotaomicron*'s 8 capsular polysaccharides, *CPS4*, promotes biofilm formation *in vitro*, indicating that capsules mediate yet another important aspect of bacterial physiology.

Bacterial capsular polysaccharides are known to negatively affect biofilm formation by masking surface structures involved in adhesion in many bacteria (27–31). It was shown, for instance, that *Escherichia coli* capsular polysaccharides inhibit adhesion and auto-aggregation by masking the short autotransporter adhesin antigen 43 as well as the type III secretion system required for attachment in enteropathogenic *E. coli* (EPEC) (32, 33). The fact that CPS4 is the most expressed capsule in the tested laboratory conditions and *in vivo* (20) probably explains why it was the only capsule of *B. thetaiotaomicron* we identified by random transposon mutagenesis screening for increased biofilm formation.

In an adhering Δ CPS4 strain, 30% of the bacteria are acapsulated, indicating that occurrence of only a subpopulation of acapsulated cells is enough to induce biofilm formation. In *Bacteroides fragilis*, acapsular cells were previously shown to aggregate (17, 34), and we also observed that a completely acapsular strain of *B. thetaiotaomicron* lacking all 8 capsules (Δ CPS1-8) displays a strong aggregation phenotype. Aggregation and cell-to-cell adhesion is an essential part of the biofilm formation maturation process, and free-floating aggregates and air-liquid interface pellicles formed in the absence of any solid surface are considered bona fide biofilms (35). Although the capacity of acapsular bacteria to bind surfaces was not addressed in this work, we hypothesized that, in the absence of a capsule, cell-to-cell interactions are strong drivers of *B. thetaiotaomicron* biofilm formation. However, due to the protective roles of *Bacteroides* capsules, acapsular strains are rapidly outcompeted by WT strain in axenic mouse colonization (17, 34, 36). Monitoring the expression of the 8 *B. thetaiotaomicron* capsules by qRT-PCR does not allow detection of acapsular bacteria, as there is no marker of acapsular cells. However, colonization of axenic mice with a mix composed of an acapsular mutant and 8 strains each expressing a single capsule showed that a small amount of acapsular cells was found to persist in the lumen of the small intestine of two out of five mice, potentially due to a decreased immune system pressure allowing the acapsular cells to survive (20). Whether the presence of an acapsular population of bacteria naturally arises and persists in the mammalian gut remains to be demonstrated, and it is still unclear whether increased adhesion capacity of acapsular bacteria is a relevant mechanism by which *B. thetaiotaomicron* can modify its biofilm formation capacity and biofilm-associated resistance to stress.

Bacteroides sp. capsular loci are regulated by a complex transcriptional network involving stochastic inversion of some capsule promoters (17, 37), transcriptional cross-regulation between capsular regulators UpxY and UpxZ (18, 19), and cross talk between polysaccharide utilization loci and capsules through common sigma factors (37). It is also impacted by a range of environmental parameters such as diet, community composition, and host physiology (20, 38, 39). In particular, expression of capsule 4 in mice has been shown to be increased *in vivo* compared to *in vitro* in a high-fiber diet, but it is decreased in the suckling period compared to the weaned period (38, 39), and it is strongly impacted by the immune system (20). Moreover, a transcriptional analysis comparing planktonic cells with biofilms grown on chemostats for 8 days previously showed that CPS4 is downregulated in *B. thetaiotaomicron* biofilms (15).

Random transposon mutagenesis in the Δ CPS4 strain identified capsule regulation as the main parameter governing biofilm formation in our conditions. We show that *BT1357*, encoding the UpxZ homolog of *CPS4*, represses transcription of *CPS2*. UpxZ proteins repress the transcription of nonadjacent capsular operon by interacting with the antiterminator UpxY proteins, necessary for the full transcription of their cognate capsules (18, 19). *BT1357* therefore most likely only interferes with *BT0462*, the UpxY homolog of *CPS2*. Whereas the complex interplay between UpxY and UpxZ homologs of *B. fragilis* was very well described, it is, to our knowledge, the first description of the precise inhibition pattern of a *B. thetaiotaomicron* UpxZ homolog (18, 19).

In addition to *BT1357*, we have identified that deletion of *BT2934* impacted capsule production. *BT2934-2947* is the protein O-glycosylation locus of *B. thetaiotaomicron* (21, 22). This locus is composed of a *wzx* oligosaccharide flippase (*BT2934*) and glycosyl transferases, and its homolog in *B. fragilis*, the *BF4298-4306* locus, was shown to be

required for both *in vivo* and *in vitro* fitness in *B. fragilis* (21, 22). Accordingly, *BT2934* was previously shown to be important in both *in vitro* and *in vivo* competition experiments between complex communities of *B. thetaiotaomicron* transposon mutants (23) and was recently described as a putative essential gene (40). Our results confirm both the role of the $\Delta BT2934$ -2938 locus in protein glycosylation and the decreased colonization capacity of a $\Delta BT2934$ -2938 mutant in axenic mice in competition with the WT strain. However, deletion of *BT2934*-2938 in the $\Delta CPS4$ background had no effect on the colonization capacity of this strain. Although we never succeeded in deleting *BT2934* alone, deletion of *BT2934*-2938 in the WT and the $\Delta CPS4$ background did not lead to any growth defect *in vitro*, suggesting that deleting *BT2935*-2938 might somehow alleviate the fitness cost associated with the loss of *BT2934*.

We showed that deletion of *BT2934* impacted capsule production independently of protein glycosylation, as complementation by *BT2934* is sufficient to restore the $\Delta CPS4$ biofilm formation phenotype but not the lack of protein glycosylation. The mechanism by which *BT2934* impacts capsule production remains to be elucidated. Because overexpression of *BT2934* in each strain only expressing a single CPS type did not lead to general acapsulation, we hypothesize that *BT2934* does not directly inhibit capsule production. *BT2934* catalyzes the flipping of an oligosaccharide bound to an undecaprenyl-phosphate molecule across the membrane. As oligosaccharide flipping is also required for lipopolysaccharide and capsular synthesis, we speculate that these three processes might compete for undecaprenyl-phosphate or sugar moiety availability. Thus, limiting protein glycosylation by removing *BT2934* could favor the production of some capsules.

While our random transposon mutagenesis in $\Delta CPS4$ was not saturating, it is surprising that all identified biofilm-deficient mutants corresponded to insertions affecting capsule production rather than a putative adhesion factor unmasked in acapsulated bacteria. This could be indicative of the role played by purely electrostatic interactions between acapsulated bacteria or mediated by multiple and potentially redundant adhesive surface structures.

We show that expression of all capsular polysaccharide of *B. thetaiotaomicron* hindered biofilm formation, except for CPS8 that, rather, promoted biofilm formation. Consistently, CPS8 expression was shown to be upregulated in 8-day chemostat-grown biofilms (15), while capsules 1, 3, 4, and 6 were downregulated. CPS8 might be either an adhesive capsule or a loose capsule that does not mask adhesion factors. However, if CPS8 did not mask adhesion factors, we would expect the CPS8-only strain to adhere like $\Delta CPS1$ -8, but CPS8-only formed less biofilm than $\Delta CPS1$ -8, and it did not aggregate overnight. This suggests that capsule 8 could be a capsule providing adhesion capacity on its own. Interestingly, CPS8 is the only capsular locus of *B. thetaiotaomicron* containing homologs of FimA, the major component of type V pilus (41). Type V pili are widely found in *Bacteroidetes*, and they were shown to mediate adhesion in *Porphyromonas gingivalis* (42, 43). Moreover, we previously showed that another homolog of FimA, BT3147, mediated biofilm formation in *B. thetaiotaomicron* upon truncation of the last 9 amino acids (13). CPS8 is expressed to low levels in axenic mice mono-colonized with *B. thetaiotaomicron*, and to slightly higher levels in mice colonized with complex communities, suggesting it might confer an advantage to *B. thetaiotaomicron* when competing with other bacteria for colonization. Whereas a strain expressing only CPS8 is rapidly outcompeted by the WT in the *in vivo* competition experiment, some population of CPS8-only bacteria can be found in the lumen of the small intestine in some mice, reminiscent of the acapsular strain localization (20).

Although several studies described biofilm-like structures in the intestine (44, 45), the relevance of a biofilm organization of the gut microbiota is still controversial. It was nevertheless suggested that surface adhesion, the initial step leading to biofilm formation, could provide benefits for host colonization. Compared to free-floating bacteria, bacteria adhering to food particles could contribute to digestion by optimizing the degradation of complex sugars (46, 47). Moreover, many bacteria were shown to be able to adhere to mucins, the main component of the host mucus layer (48), and this

adhesion is believed to be critical to prevent fast shedding of the bacteria with luminal content (49). Finally, both aggregate and biofilm formation were shown to increase bacterial resistance to several stresses and thus might contribute to bacterial survival in the harsh gut environment (35). In this study, we found no evidence that higher *in vitro* adhesion would lead to better colonization of axenic mice. However, we assessed the abundance of each strain by enumerating bacteria in the feces of mice, even though feces composition only partially recapitulates gut microbiota composition (50). In particular, we can imagine that cells with higher adhesion would not be shed in the feces as much as cells with low adhesion, mimicking a colonization defect. Moreover, besides biofilm formation, *CPS4* and *BT2934* participate in other significant processes, i.e., interactions with the immune system and protein glycosylation, respectively. Therefore, we cannot exclude that the loss of *in vivo* fitness of $\Delta CPS4$ and $\Delta BT2934-38$ strains might be due to the consequence of these deletions on non-biofilm-related functions, overriding any benefit coming from increased biofilm formation.

In this study, we have shown that capsule regulation is a major determinant of biofilm formation. We described a transcriptional inhibition of *CPS2* by the *UpxZ* homolog of the *CPS4* locus and showed that competition between protein glycosylation and capsule production could constitute another layer of an already very complex capsule regulatory system. Further investigation of the mechanisms of biofilm formation in the gut commensal *B. thetaiotaomicron* will allow us to address the physiological adaptations of these bacteria within an anaerobic biofilm.

MATERIALS AND METHODS

Bacterial strains and growth conditions. The bacterial strains used in this study are listed in Table S2. *B. thetaiotaomicron* was grown in brain heart infusion salt (BHIS) broth (51) supplemented with erythromycin (15 $\mu\text{g}/\text{ml}$ [erm]), tetracycline (2.5 $\mu\text{g}/\text{ml}$ [tet]), gentamicin (200 $\mu\text{g}/\text{ml}$ [gent]), or 5'-fluoro-2'-deoxyuridine (200 $\mu\text{g}/\text{ml}$ [FdUR]) when required and incubated at 37°C in anaerobic conditions using jars with anaerobic atmosphere generators (GENbag anaerobic; bioMérieux, ref. 45534) or in a C400M Ruskinn anaerobic-microaerophilic station. *Escherichia coli* S17 λ pir was grown in Miller's lysogeny broth (LB) (Corning) supplemented with ampicillin (100 $\mu\text{g}/\text{ml}$) when required and incubated at 37°C with 180 rpm shaking. Cultures on solid medium were done in BHIS broth with 1.5% agar, and antibiotics were added when needed. Bacteria were always streaked from glycerol stock on BHIS agar before being grown in liquid cultures. All media and chemicals were purchased from Sigma-Aldrich unless indicated otherwise. All experiments and genetic constructions of *B. thetaiotaomicron* were made in the VPI-5482 Δtdk strain, which was developed for a 2-step selection procedure of unmarked gene deletion by allelic exchange as previously described (52). Therefore, the VPI-5482 Δtdk is referred to as the wild type in this study.

96-well crystal violet biofilm formation assay. Overnight culture was diluted to an optical density at 600 nm (OD_{600}) of 0.05 in 100 μl BHIS broth and inoculated in technical duplicates in polystyrene Greiner round-bottom 96-well plates. The wells at the border of the plates were filled with 200 μl water to prevent evaporation. Incubation was done at 37°C in anaerobic conditions for 48 h. Then, 25 μl of Bouin solution (picric acid 0.9%, formaldehyde 9%, and acetic acid 5%; HT10132, Sigma-Aldrich) was added directly to each well before removal of the supernatant to prevent the washing out of large aggregates. Cultures were fixed for 10 min, and then the wells were washed once with water by immersion and flicking, and the biofilm was stained with 125 μl 1% crystal violet (V5265; Sigma-Aldrich) for 10 min. Crystal violet solution was removed by flicking, and biofilms were washed twice with water. Stained biofilms were resuspended in a 1:4 acetone:ethanol mix, and absorbance at 575 nm was measured using a Tecan infinite M200 PRO plate reader.

Targeted mutagenesis. Deletion mutants were constructed using the previously described vector for allelic exchange in *B. thetaiotaomicron*—pExchange-*tdk* (52). A list of all the primers used in this study can be found in Table S3. Briefly, a 1-kb region upstream and downstream of the target sequence and pExchange-*tdk* were amplified by PCR using Phusion Flash high-fidelity PCR master mix (Thermo Fischer Scientific; F548). All three fragments were ligated using a Gibson assembly as follows: the inserts and the plasmids were mixed with Gibson master mix 2 \times (100 μl 5 \times ISO buffer, 0.2 μl 10,000 U/ml T5 exonuclease [NEB catalog number M0363S], 6.25 μl 2,000 U/ml Phusion HF polymerase [NEB catalog number M0530S], 50 μl 40,000 U/ml *Taq* DNA ligase [NEB catalog number M0208S], and 87 μl dH₂O for 24 reactions) and incubated at 50°C for 35 min. The resulting mix was transformed in *E. coli* S17 λ pir that was used to deliver the vector to *B. thetaiotaomicron* by conjugation. Conjugation was carried out by mixing exponentially grown cultures ($\text{OD}_{600} = 0.6$) of the donor and the recipient strain in a 2:1 ratio. The mixture was spotted on BHIS-agar plates and incubated at 37°C in aerobic conditions overnight. The mix was then streaked on BHIS agar supplemented with antibiotic—for selection of *B. thetaiotaomicron* transconjugants that had undergone the first recombination event—and gentamicin to ensure exclusion of any *E. coli* growth. Eight of the resulting colonies were grown overnight in BHIS broth with no antibiotic to allow a second recombination event, and the culture was plated on BHIS agar plates

supplemented with FdUR to select for loss of plasmid. The resulting deletion mutants were confirmed by PCR and sequencing.

We used the pNBU2-bla-erm vector (53) for complementation, which inserts in the 5' untranslated region of the tRNA-Ser, in which we previously cloned the constitutive promoter of *BT1311* encoding the sigma factor RpoD (13). We constructed a pNBU2-bla-tet vector by replacing the erythromycin resistance gene by a tetracycline resistance gene from the pExchange-tet plasmid using Gibson assembly (see above). Target genes were amplified by PCR using Phusion Flash high-fidelity PCR master mix from start codon to stop codon, and they were cloned after *BT1311* promoter by Gibson assembly. The Gibson mix was transformed in *E. coli* S17λpir, and the resulting *E. coli* was used to transfer the plasmid to *B. thetaiotaomicron* by conjugation (see above).

Transposon mutagenesis. pSAMbt, the previously published tool for random mariner-based transposon mutagenesis in *B. thetaiotaomicron* (23), was conjugated in *B. thetaiotaomicron* as described above. After streaking on BHIS-erm-genta agar plates, isolated colonies were resuspended in 100 μl BHIS broth in 96-well plates, grown overnight, and tested for biofilm formation as described above. The selected clones were then streaked on a fresh BHIS-erm-genta agar plate, and 3 isolated colonies were tested for biofilm formation to ensure that no mix of transposon mutants had occurred during preparation of the library. The genomic DNA of the validated clones was extracted using a DNeasy blood and tissue kit (Qiagen) and sent for whole-genome sequencing at the Mutualized Platform for Microbiology of the Institut Pasteur.

Electronic microscopy and numbering of acapsulated bacteria. Overnight cultures were adjusted to 1 ml and an OD₆₀₀ of 1.5. Cells were treated as described by Jacques and Foiry (54) for capsule observation as follows: cultures were resuspended in 5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.2) and incubated at room temperature for 2 h. Cells were then washed three times in 0.1 M cacodylate buffer (pH 7.2) and fixed 30 min in 1 mg/ml ferritin in 0.1 M cacodylate buffer (pH 7.2). Cells were washed one last time in 0.1 M cacodylate buffer (pH 7.2) and sent for transmission electronic microscopy at the electronic microscopy platform IBISA of the University of Tours (<https://microscopies.med.univ-tours.fr/>). Acapsulated cells were counted by hand using the Fiji cell counter plugin.

India ink stain. For the India ink stain, 5 μl of overnight cultures were mixed with 3 μl India ink directly on a Superfrost Plus glass microscopy slide (Thermo Fischer Scientific) and left to dry for 2 min. The excess liquid was removed with a paper towel after addition of the coverslip, and the cells were observed with a photonic microscope at ×1000 magnification.

Observation of aggregates by light microscopy. First, 1 μl of the bottom of an overnight sedimented culture were mixed with 3 μl phosphate buffered saline (PBS) buffer and dropped on a on Superfrost Plus glass microscopy slide (Thermo Fischer Scientific), and then it was covered with a coverslip. The samples were observed with a photonic microscope at ×400 magnification.

RNA extraction. Overnight cultures were mixed with RNAprotect bacteria reagent (Qiagen) at a 1:2 volume ratio. The mix was incubated for 5 min at room temperature and then spun down for 10 min at 5,000 × g. The pellet was kept at -80°C. RNA was extracted from the pellet using a FastRNA Pro Blue kit (MP). The pellet was resuspended in 1 ml RNAPro and mixed with lysing matrix B. Cells were broken using FastPrep instrument at 40 s, speed 6, twice at 4°C. The lysate was centrifuged for 10 min at 4°C at 12,000 × g, and the supernatant was collected and mixed with 300 μl of chloroform. After 5 min of incubation at room temperature, the mix was centrifuged at 12,000 × g at 4°C for 5 min. The upper phase was transferred to a tube containing 500 μl cold 100% ethanol, and the nucleic acids were precipitated for 1 h at -20°C. The tubes were centrifuged at 12,000 × g at 4°C for 15 min, and the pellet was washed in 500 μl cold 75% ethanol. After centrifugation at 12,000 × g and 4°C for 5 min, the ethanol was removed, and the pellet was air-dried. Then, 60 μl of RNA-free water was added to resuspend the nucleic acid, and we treated it with Turbo DNase from the Turbo DNA-free kit (Thermo Fischer Scientific; product number AM1907) for 1.5 h. Then, the enzyme was inactivated using Turbo DNase inactivator for 2 min at room temperature, and the extracted RNA was kept at -20°C.

qRT-PCR. We performed reverse transcription using the first-strand cDNA synthesis kit for RT-PCR (AMV) (Sigma-Aldrich) and the protocol described by the supplier. Briefly, 500 μg RNA previously boiled for 15 min at 65°C was mixed with 2 μl 10× reaction buffer, 4 μl MgCl₂ 25 mM, 2 μl dNTP mix at 10 mM each, 1 μl 3' primer 20 μM, 1 μl RNase inhibitor 50 U/μl, and 0.8 AMV reverse transcriptase and water. The mix was incubated at 42°C for 1.5 h, and the enzyme was inactivated by heating to 99°C for 5 min. qPCR was performed using SYBR green PCR master mix (Life Technologies). cDNA was mixed with SYBR green master mix as described by the supplier and with corresponding primers in technical duplicates in 384-well plates. The qPCR was performed using the QuantStudio 6 Flex real-time PCR system (Thermo Fischer Scientific) and the "ΔΔCt method" program. We followed 16s rRNA and RpoB as housekeeping genes for normalization.

Staining of glycosylated proteins. Overnight cultures were adjusted to 1 ml at an OD₆₀₀ of 1, spun down and resuspended in 100 μl 1× Laemmli-β-mercaptoethanol lysis buffer (Bio-Rad), and boiled for 5 min at 95°C. Then, 10 μl was run on Mini-PROTEAN TGX stain-free TM precast gels (Bio-Rad) in 1× TGX buffer for 40 min at 170 V. The gel was then stained using a Pro-Q Emerald 300 staining for glycoproteins kit (Invitrogen) following the procedure described by the supplier.

Coclonization of axenic mice. Animal experiments were done at the Animalerie Axénique de MICALIS (ANAXEM) platform (Microbiologie de l'Alimentation au Service de la Santé [MICALIS], Jouy-en-Josas, France) according to official authorization number 3441-2016010614307552 delivered by the French Ministry of Education Nationale, Enseignement Supérieur et Recherche. The protocol was approved by a local ethics committee on animal experimentation (committee number 45). All animals were housed in flexible-film isolators (Getinge-La Calhène, Vendôme, France) with controlled environ-

mental conditions (light/dark cycle of 12 h/12 h, temperature between 20 and 22°C, humidity between 45% and 55%). Mice were provided with sterile tap water and a gamma-irradiated standard diet (R03-40; S.A.F.E., Augy, France) *ad libitum*. Their bedding was composed of wood shavings, and they were also given cellulose sheets as enrichment.

For each combination performed in separate isolators, groups of 5 male C3H/HeN germfree mice (6 to 11 weeks old) were gavaged with 200 μ l bacterial suspensions containing 100 cells of each of the two strains we coinoculated. One of the strains was conjugated with the pNBU2-bla-erm plasmid, and the other, with the pNBU2-bla-tet plasmid so that they contained a different antibiotic resistance marker for later distinction. One of the combinations (WT [ermR] versus Δ CPS4 [tetR]) was performed twice (10 mice total). We plated the mix used for gavage onto BHIS agar plates with erythromycin or with tetracycline to check the initial ratio. When it was not 1:1, we corrected the measured abundance according to the ratio we had effectively used. At 24, 48, and 72 h after inoculation, feces were collected, split into two tubes, and weighed. One of the tubes was homogenized in 1 ml of BHIS, and serial dilutions were plated onto BHIS agar plates with erythromycin or with tetracycline. The abundance of each strain in the feces was measured by counting the CFU growing on each type of plate using an automated plater (easySpiral; Interscience, France) and counter (Scan500; Interscience, France). The other tube was dried in a speed vac concentrator (Savant, USA) and weighed. This allowed us to calculate the percentage humidity of the feces we were using for each mouse and each condition and to infer the dry weight of the feces used for CFU numbering. We divided the number of bacteria obtained by CFU counting by the dry weight of the feces they were collected from.

Growth curve. Overnight cultures were diluted to 0.05 OD₆₀₀ in 200 μ l BHIS, which had previously been incubated in anaerobic conditions overnight to remove dissolved oxygen, in Greiner flat-bottom 96-well plates. A plastic adhesive film (adhesive sealing sheet; Thermo Fisher Scientific, AB0558) was added on top of the plate inside the anaerobic station, and the plates were then incubated in a Tecan Infinite M200 Pro spectrophotometer for 24 h at 37°C. The OD₆₀₀ was measured every 30 min after 900 s orbital shaking of 2 mm amplitude.

Statistical analyses. Statistical analyses were performed using either R and Rstudio software or GraphPad Prism 8 for Mac OS (GraphPad Software, Inc.). We used only nonparametric tests. For *in vivo* experiments, 5 to 10 mice were used in 1 or 2 independent experiments. For all other experiments, at least 6 biological replicates in at least 2 independent experiments were used. A cutoff *P* value of 5% was used for all tests. *, *P* < 0.05; **, *P* < 0.05; ***, *P* < 0.005.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

FIG S1, TIF file, 2.5 MB.

FIG S2, TIF file, 2.5 MB.

FIG S3, TIF file, 2.4 MB.

FIG S4, TIF file, 2.6 MB.

FIG S5, TIF file, 2.7 MB.

TABLE S1, PDF file, 0.1 MB.

TABLE S2, PDF file, 0.2 MB.

TABLE S3, PDF file, 0.1 MB.

ACKNOWLEDGMENTS

We are grateful to Andy Goodman and Justin Sonnenburg for providing the genetic tools used in this study and to Eric Martens for generously providing the *B. thetaiotaomicron* capsule mutants and mono-expressing strains. We are also very thankful to Laurie Comstock for comments on the manuscript. We thank the members of the animal facilities of INRAE-Jouy-en-Josas (Anaxem, Micalis) for their help with *in vivo* experiments.

This work was supported by an Institut Pasteur grant and by the French government's Investissement d'Avenir Program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" (grant ANR-10-LABX-62-IBEID) and the Fondation pour la Recherche Médicale (grant DEQ20180339185). N. Béchon was supported by a MENESR (Ministère Français de l'Éducation Nationale, de l'Enseignement Supérieur et de la Recherche) fellowship. J. Mihajlovic was supported by the Pasteur Paris University International Doctoral Program and the Fondation pour la Recherche Médicale (grant FDT20160435523).

N.B., J.M., S.V.-F., and F.C. performed the experiments; N.B., J.M., C.B., and J.-M.G. designed the experiments and analyzed the data. J.-M.G. and P.L. provided resources and funding. N.B., J.M., and J.-M.G. wrote the manuscript.

We declare no competing financial interests.

REFERENCES

- Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. 2005. Diversity of the human intestinal microbial flora. *Science* 308:1635–1638. <https://doi.org/10.1126/science.1110591>.
- Hooper LV, Midtvedt T, Gordon JI. 2002. How host-microbial interactions shape the nutrient environment of the mammalian intestine. *Annu Rev Nutr* 22:283–307. <https://doi.org/10.1146/annurev.nutr.22.011602.092259>.
- Comstock LE, Coyne MJ. 2003. *Bacteroides thetaiotaomicron*: a dynamic, niche-adapted human symbiont. *Bioessays* 25:926–929. <https://doi.org/10.1002/bies.10350>.
- Wexler AG, Goodman AL. 2017. An insider's perspective: *Bacteroides* as a window into the microbiome. *Nat Microbiol* 2:17026. <https://doi.org/10.1038/nmicrobiol.2017.26>.
- Porter NT, Luis AS, Martens EC. 2018. *Bacteroides thetaiotaomicron*. *Trends Microbiol* 26:966–967. <https://doi.org/10.1016/j.tim.2018.08.005>.
- Hooper LV, Stappenbeck TS, Hong CV, Gordon JI. 2003. Angiogenins: a new class of microbicidal proteins involved in innate immunity. *Nat Immunol* 4:269–273. <https://doi.org/10.1038/ni888>.
- Kelly D, Campbell JI, King TP, Grant G, Jansson EA, Coutts AG, Pettersson S, Conway S. 2004. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. *Nat Immunol* 5:104–112. <https://doi.org/10.1038/ni1018>.
- Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. 2001. Molecular analysis of commensal host-microbial relationships in the intestine. *Science* 291:881–884. <https://doi.org/10.1126/science.291.5505.881>.
- Zocco MA, Ainora ME, Gasbarrini G, Gasbarrini A. 2007. *Bacteroides thetaiotaomicron* in the gut: molecular aspects of their interaction. *Dig Liver Dis* 39:707–712. <https://doi.org/10.1016/j.dld.2007.04.003>.
- Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. 2007. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc Natl Acad Sci U S A* 104:13780–13785. <https://doi.org/10.1073/pnas.0706625104>.
- de Vos WM. 2015. Microbial biofilms and the human intestinal microbiome. *NPJ Biofilms Microbiomes* 1:15005. <https://doi.org/10.1038/nnpjbiofilms.2015.5>.
- Macfarlane S, Bahrami B, Macfarlane GT. 2011. Mucosal biofilm communities in the human intestinal tract. *Adv Appl Microbiol* 75:111–143. <https://doi.org/10.1016/B978-0-12-387046-9.00005-0>.
- Mihajlovic J, Bechon N, Ivanova C, Chain F, Almeida A, Langella P, Beloin C, Ghigo JM. 2019. A putative type V pilus contributes to *Bacteroides thetaiotaomicron* biofilm formation capacity. *J Bacteriol* 201. <https://doi.org/10.1128/jb.00650-18>.
- Reis ACM, Silva JO, Laranjeira BJ, Pinheiro AQ, Carvalho CBM. 2014. Virulence factors and biofilm production by isolates of *Bacteroides fragilis* recovered from dog intestinal tracts. *Braz J Microbiol* 45:647–650. <https://doi.org/10.1590/s1517-83822014000200037>.
- TerAvest MA, He Z, Rosenbaum MA, Martens EC, Cotta MA, Gordon JI, Angenent LT. 2014. Regulated expression of polysaccharide utilization and capsular biosynthesis loci in biofilm and planktonic *Bacteroides thetaiotaomicron* during growth in chemostats. *Biotechnol Bioeng* 111:165–173. <https://doi.org/10.1002/bit.24994>.
- Xu J, Bjursell MK, Himrod J, Deng S, Carmichael LK, Chiang HC, Hooper LV, Gordon JI. 2003. A genomic view of the human-*Bacteroides thetaiotaomicron* symbiosis. *Science* 299:2074–2076. <https://doi.org/10.1126/science.1080029>.
- Coyne MJ, Comstock LE. 2008. Niche-specific features of the intestinal Bacteroidales. *J Bacteriol* 190:736–742. <https://doi.org/10.1128/JB.01559-07>.
- Chatzidaki-Livanis M, Coyne MJ, Comstock LE. 2009. A family of transcriptional antitermination factors necessary for synthesis of the capsular polysaccharides of *Bacteroides fragilis*. *J Bacteriol* 191:7288–7295. <https://doi.org/10.1128/JB.00500-09>.
- Chatzidaki-Livanis M, Weinacht KG, Comstock LE. 2010. Trans locus inhibitors limit concomitant polysaccharide synthesis in the human gut symbiont *Bacteroides fragilis*. *Proc Natl Acad Sci U S A* 107:11976–11980. <https://doi.org/10.1073/pnas.1005039107>.
- Porter NT, Canales P, Peterson DA, Martens EC. 2017. A subset of polysaccharide capsules in the human symbiont *Bacteroides thetaiotaomicron* promote increased competitive fitness in the mouse gut. *Cell Host Microbe* 22:494–506.e498. <https://doi.org/10.1016/j.chom.2017.08.020>.
- Fletcher CM, Coyne MJ, Villa OF, Chatzidaki-Livanis M, Comstock LE. 2009. A general O-glycosylation system important to the physiology of a major human intestinal symbiont. *Cell* 137:321–331. <https://doi.org/10.1016/j.cell.2009.02.041>.
- Coyne MJ, Fletcher CM, Chatzidaki-Livanis M, Posch G, Schaffer C, Comstock LE. 2013. Phylum-wide general protein O-glycosylation system of the Bacteroidetes. *Mol Microbiol* 88:772–783. <https://doi.org/10.1111/mmi.12220>.
- Goodman AL, McNulty NP, Zhao Y, Leip D, Mitra RD, Lozupone CA, Knight R, Gordon JI. 2009. Identifying genetic determinants needed to establish a human gut symbiont in its habitat. *Cell Host Microbe* 6:279–289. <https://doi.org/10.1016/j.chom.2009.08.003>.
- Peterson DA, McNulty NP, Guruge JL, Gordon JI. 2007. IgA response to symbiotic bacteria as a mediator of gut homeostasis. *Cell Host Microbe* 2:328–339. <https://doi.org/10.1016/j.chom.2007.09.013>.
- Hsieh S, Porter NT, Donermeyer DL, Horvath S, Strout G, Saunders BT, Zhang N, Zinselmeyer B, Martens EC, Stappenbeck TS, Allen PM. 2020. Polysaccharide capsules equip the human symbiont *Bacteroides thetaiotaomicron* to modulate immune responses to a dominant antigen in the intestine. *J Immunol* 204:1035–1046. <https://doi.org/10.4049/jimmunol.1901206>.
- Porter NT, Hryckowian AJ, Merrill BD, Gardner JO, Singh S, Sonnenburg JL, Martens EC. 2019. Multiple phase-variable mechanisms, including capsular polysaccharides, modify bacteriophage susceptibility in *Bacteroides thetaiotaomicron*. *bioRxiv* <https://doi.org/10.1101/521070>.
- Gillaspay AF, Lee CY, Sau S, Cheung AL, Smeltzer MS. 1998. Factors affecting the collagen binding capacity of *Staphylococcus aureus*. *Infect Immun* 66:3170–3178. <https://doi.org/10.1128/IAI.66.7.3170-3178.1998>.
- Joseph LA, Wright AC. 2004. Expression of *Vibrio vulnificus* capsular polysaccharide inhibits biofilm formation. *J Bacteriol* 186:889–893. <https://doi.org/10.1128/jb.186.3.889-893.2004>.
- Yi K, Rasmussen AW, Gudlavalletti SK, Stephens DS, Stojilkovic I. 2004. Biofilm formation by *Neisseria meningitidis*. *Infect Immun* 72:6132–6138. <https://doi.org/10.1128/IAI.72.10.6132-6138.2004>.
- Schembri MA, Dalsgaard D, Klemm P. 2004. Capsule shields the function of short bacterial adhesins. *J Bacteriol* 186:1249–1257. <https://doi.org/10.1128/jb.186.5.1249-1257.2004>.
- Qin L, Kida Y, Imamura Y, Kuwano K, Watanabe H. 2013. Impaired capsular polysaccharide is relevant to enhanced biofilm formation and lower virulence in *Streptococcus pneumoniae*. *J Infect Chemother* 19:261–271. <https://doi.org/10.1007/s10156-012-0495-3>.
- Schembri MA, Hjerrild L, Gjermansen M, Klemm P. 2003. Differential expression of the *Escherichia coli* autoaggregation factor antigen 43. *J Bacteriol* 185:2236–2242. <https://doi.org/10.1128/jb.185.7.2236-2242.2003>.
- Shifrin Y, Peleg A, Ilan O, Nadler C, Kobi S, Baruch K, Yerushalmi G, Berdichevsky T, Altuvia S, Elgrably-Weiss M, Abe C, Knutton S, Sasakawa C, Ritchie JM, Waldor MK, Rosenshine I. 2008. Transient shielding of intimin and the type III secretion system of enterohemorrhagic and enteropathogenic *Escherichia coli* by a group 4 capsule. *J Bacteriol* 190:5063–5074. <https://doi.org/10.1128/JB.00440-08>.
- Liu CH, Lee SM, Vanlare JM, Kasper DL, Mazmanian SK. 2008. Regulation of surface architecture by symbiotic bacteria mediates host colonization. *Proc Natl Acad Sci U S A* 105:3951–3956. <https://doi.org/10.1073/pnas.0709266105>.
- Kragh KN, Hutchison JB, Melaugh G, Rodesney C, Roberts AE, Irie Y, Jensen PO, Diggle SP, Allen RJ, Gordon V, Bjarnsholt T. 2016. Role of multicellular aggregates in biofilm formation. *mBio* 7:e00237. <https://doi.org/10.1128/mBio.00237-16>.
- Porter NT, Martens EC. 2017. The critical roles of polysaccharides in gut microbial ecology and physiology. *Annu Rev Microbiol* 71:349–369. <https://doi.org/10.1146/annurev-micro-102215-095316>.
- Krinos CM, Coyne MJ, Weinacht KG, Tzianabos AO, Kasper DL, Comstock LE. 2001. Extensive surface diversity of a commensal microorganism by multiple DNA inversions. *Nature* 414:555–558. <https://doi.org/10.1038/35107092>.
- Sonnenburg JL, Xu J, Leip DD, Chen CH, Westover BP, Weatherford J, Buhler JD, Gordon JI. 2005. Glycan foraging in vivo by an intestine-adapted bacterial symbiont. *Science* 307:1955–1959. <https://doi.org/10.1126/science.1109051>.
- Bjursell MK, Martens EC, Gordon JI. 2006. Functional genomic and metabolic studies of the adaptations of a prominent adult human gut

- symbiont, *Bacteroides thetaiotaomicron*, to the suckling period. *J Biol Chem* 281:36269–36279. <https://doi.org/10.1074/jbc.M606509200>.
40. Liu H, Price MN, Carlson HK, Chen Y, Ray J, Shiver AL, Petzold CJ, Huang KC, Arkin AP, Deutschbauer AM. 2019. Large-scale chemical-genetics of the human gut bacterium *Bacteroides thetaiotaomicron*. *bioRxiv* <https://doi.org/10.1101/573055>.
 41. Xu Q, Shoji M, Shibata S, Naito M, Sato K, Elsliger M-A, Grant JC, Axelrod HL, Chiu H-J, Farr CL, Jaroszewski L, Knuth MW, Deacon AM, Godzik A, Lesley SA, Curtis MA, Nakayama K, Wilson IA. 2016. A distinct type of pilus from the human microbiome. *Cell* 165:690–703. <https://doi.org/10.1016/j.cell.2016.03.016>.
 42. Zheng C, Wu J, Xie H. 2011. Differential expression and adherence of *Porphyromonas gingivalis* FimA genotypes. *Mol Oral Microbiol* 26: 388–395. <https://doi.org/10.1111/j.2041-1014.2011.00626.x>.
 43. Hospenthal MK, Costa TRD, Waksman G. 2017. A comprehensive guide to pilus biogenesis in Gram-negative bacteria. *Nat Rev Microbiol* 15: 365–379. <https://doi.org/10.1038/nrmicro.2017.40>.
 44. Macfarlane MJ, Hopkins GT, Macfarlane S. 2000. Bacterial growth and metabolism on surfaces in the large intestine. *Microb Ecol Health Dis* 12:64–72. <https://doi.org/10.1080/089106000750060314>.
 45. Palestrant D, Holzknecht ZE, Collins BH, Parker W, Miller SE, Bollinger RR. 2004. Microbial biofilms in the gut: visualization by electron microscopy and by acridine orange staining. *Ultrastruct Pathol* 28:23–27. <https://doi.org/10.1080/01913120490275196>.
 46. Macfarlane S, Macfarlane GT. 2006. Composition and metabolic activities of bacterial biofilms colonizing food residues in the human gut. *Appl Environ Microbiol* 72:6204–6211. <https://doi.org/10.1128/AEM.00754-06>.
 47. Macfarlane S, McBain AJ, Macfarlane GT. 1997. Consequences of biofilm and sessile growth in the large intestine. *Adv Dent Res* 11:59–68. <https://doi.org/10.1177/08959374970110011801>.
 48. Sicard JF, Le Bihan G, Vogeeler P, Jacques M, Harel J. 2017. Interactions of intestinal bacteria with components of the intestinal mucus. *Front Cell Infect Microbiol* 7:387. <https://doi.org/10.3389/fcimb.2017.00387>.
 49. Sonnenburg JL, Angenent LT, Gordon JL. 2004. Getting a grip on things: how do communities of bacterial symbionts become established in our intestine? *Nat Immunol* 5:569–573. <https://doi.org/10.1038/ni1079>.
 50. Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashardes S, Kotler E, Zur M, Regev-Lehavi D, Briker RB, Federici S, Cohen Y, Linevsky R, Rothschild D, Moor AE, Ben-Moshe S, Harmelin A, Itzkovitz S, Maharshak N, Shibolet O, Shapiro H, Pevsner-Fischer M, Sharon I, Halpern Z, Segal E, Elinav E. 2018. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. *Cell* 174:1388–1405.e1321. <https://doi.org/10.1016/j.cell.2018.08.041>.
 51. Bacic MK, Smith CJ. 2008. Laboratory maintenance and cultivation of bacteroides species. *Curr Protoc Microbiol* Chapter 13:Unit-13C.11. <https://doi.org/10.1002/9780471729259.mc13c01s9>.
 52. Koropatkin NM, Martens EC, Gordon JL, Smith TJ. 2008. Starch catabolism by a prominent human gut symbiont is directed by the recognition of amylose helices. *Structure* 16:1105–1115. <https://doi.org/10.1016/j.str.2008.03.017>.
 53. Wang J, Shoemaker NB, Wang G-R, Salyers AA. 2000. Characterization of a *Bacteroides* mobilizable transposon, NBU2, which carries a functional lincomycin resistance gene. *J Bacteriol* 182:3559–3571. <https://doi.org/10.1128/jb.182.12.3559-3571.2000>.
 54. Jacques M, Foiry B. 1987. Electron microscopic visualization of capsular material of *Pasteurella multocida* types A and D labeled with polycationic ferritin. *J Bacteriol* 169:3470–3472. <https://doi.org/10.1128/jb.169.8.3470-3472.1987>.